SCHEMBL995550

SCHEMBL995550

CCCC(CN)CCN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19187626 1.00
SCHEMBL171318 0.91
SCHEMBL4854735 0.88 ALDH1A1 (0.38)
Hydrochloric Acid SCHEMBL10764012 0.88 ALDH1A1 (0.50)
SCHEMBL16202951 0.88 ALDH1A1 (0.38)
Hydrochloric Acid SCHEMBL26976882 0.85 DNM1 (0.36)
SCHEMBL6897108 0.84
SCHEMBL39985 0.84
SCHEMBL14616067 0.83 ALDH1A1 (0.54)
SCHEMBL996640 0.83 ALDH1A1 (0.68)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3831372-A1 MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS Pathologica LLC (US) 2021-06-09 EP disclosed
US-10350178-B2 Methods and compositions for treatment of demyelinating diseases PATHOLOGICA LLC (US) 2019-07-16 US disclosed
EP-3473247-A1 COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS Pathologica LLC (US) 2019-04-24 EP disclosed
CN-104997762-B Oral delivery drug comprising MGBG and the method for treating disease 帕萨罗杰卡有限公司 2019-03-08 CN disclosed
CN-109432073-A Purposes of the MGBG in the drug that preparation treats or prevents progressive MS and its progress 帕萨罗杰卡有限公司 2019-03-08 CN disclosed
US-20180360783-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES PATHOLOGICA LLC 2018-12-20 US disclosed
EP-2453886-B1 PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE PATHOLOGICA LLC (US) 2018-12-12 EP disclosed
CN-105163730-B Methods and compositions for treating demyelinating diseases 帕萨罗杰卡有限公司 2018-10-30 CN disclosed
US-10085955-B2 Methods and compositions for treatment of demyelinating diseases PATHOLOGICA LLC (US) 2018-10-02 US disclosed
US-10066099-B2 Polyester-based resin composition, and molded body using the resin composition MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2018-09-04 US disclosed
US-6963010-B2 Anticancer agents; osteoporosis; autoimmune disease MEDIQUEST THERAPEUTICS, INC. (US) 2005-11-08 US disclosed
US-20050245615-A1 Composition containing polyamine transport inhibitor and use thereof MEDIQUEST THERAPEUTICS, INC. (US) 2005-11-03 US disclosed
EP-1262524-B1 Polyester based resin composition and molded product therefrom MITSUBISHI GAS CHEMICAL CO (JP) 2005-08-24 EP disclosed
US-20050176828-A1 Hydrophobic polyamine analogs and methods for their use MEDIQUEST THERAPEUTICS, INC. (US) 2005-08-11 US disclosed
US-6740376-B2 POLYAMIDE AND A POLYESTER OR A POLYAMIDE, A POLYESTER AND POLYETHYLENE TEREPHTHALATE; POLYESTER BY CONDENSATION OF A DICARBOXYLIC ACID OR DIOL HAVING A CYCLIC ACETAL SKELETON MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2004-05-25 US disclosed
EP-1373185-A2 HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE Mediquest Therapeutics, Inc. (US) 2004-01-02 EP disclosed
US-20030187276-A1 Hydrophobic polyamine analogs and methods for their use AMINEX THERAPEUTICS, INC. 2003-10-02 US disclosed
US-20030068455-A1 Polyester based resin composition and molded product therefrom MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2003-04-10 US disclosed
EP-1262524-A2 Polyester based resin composition and molded product therefrom MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2002-12-04 EP disclosed
WO-2002053519-A2 HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE MEDIQUEST THERAPEUTICS, INC. (US) 2002-07-11 WO disclosed